Regeneron Pharmaceuticals (REGN) Barclays 28th Annual Global Healthcare Conference summary

Key product performance and launches

• Dupixent achieved $17.8 billion in sales last year, up 32% year-over-year, with continued growth across all nine FDA-approved indications, including recent launches in chronic spontaneous urticaria and COPD.

• COPD launch for Dupixent is progressing well, with robust payer coverage and strong enthusiasm from pulmonologists, improving patient outcomes and quality of life.

• EYLEA HD now represents nearly half of the EYLEA franchise revenues, with market share expected to expand due to recent label enhancements and anticipated prefilled syringe approval.

• Lynozyfic, approved for late-line myeloma, shows strong early uptake and is being evaluated for broader use in earlier lines and precursor conditions.

Competitive positioning and life cycle management

• Dupixent maintains a strong competitive edge in atopic dermatitis due to its dual mode of action, broad indications, and established efficacy and safety profile.

• Life cycle management for Dupixent includes development of long-acting IL-4 and IL-13 antibodies, aiming for less frequent dosing and continued market leadership.

• EYLEA HD is positioned as the most flexible and durable anti-VEGF therapy, with the prefilled syringe expected to further enhance its adoption.

• Biosimilar competition is expected to drive declines in original EYLEA sales, but conversion to EYLEA HD and new patient uptake are mitigating factors.

Pipeline and future catalysts

• Near-term catalysts include pivotal readouts for fianlimab plus Libtayo in metastatic melanoma, geographic atrophy, and PNH, all expected within the next 12-18 months.

• Obesity program with olatorepatide demonstrated 19% weight loss in pivotal China data, with U.S. Phase III trials planned to start later this year.

• Co-formulation of olatorepatide with Praluent aims to address both weight loss and LDL cholesterol reduction, targeting an unmet need in the obesity market.

• Lynozyfic's opportunity could expand significantly as it moves into earlier lines of myeloma therapy, potentially doubling or more the addressable patient population.

• Additional pipeline milestones include Factor XI pivotal data in VTE and competitor readouts that may impact strategic direction.